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Abstract 
Background: Adult T‑cell leukemia (ATL) is a CD4+ T‑cell neoplasm with a poor prognosis. A previous study has 
shown that there is a strong correlation between the secreted matricellular protein osteopontin (OPN) level and dis‑
ease severity in ATL patients. Here, we investigated the role of OPN in ATL pathogenesis and the possible application 
of anti‑OPN monoclonal antibody (mAb) for ATL immunotherapy in NOD/Shi‑scid,IL‑2Rgnull (NOG) mice.
Results: Subcutaneous inoculation of ATL cell lines into NOG mice increased the plasma level of OPN, which sig‑
nificantly correlated with metastasis of the inoculated cells and survival time. Administration of an SVVYGLR motif‑
recognizing anti‑OPN mAb resulted in inhibition not only of tumor growth but also of tumor invasion and metastasis. 
The number of fibroblast activating protein‑positive fibroblasts was also reduced by this mAb. We then co‑inoculated 
mouse embryonic fibroblasts (MEFs) isolated from wild‑type (WT) or OPN knockout mice together with ATL‑derived 
TL‑OmI cells into the NOG mice. The mice co‑inoculated with WT MEFs displayed a significant decrease in survival 
relative to those injected with TL‑OmI cells alone and the absence of OPN in MEFs markedly improved the survival 
rate of TL‑OmI‑inoculated mice. In addition, tumor volume and metastasis were also reduced in the absence of OPN.
Conclusion: We showed that the xenograft NOG mice model can be a useful system for assessment of the physi‑
ological role of OPN in ATL pathogenesis. Using this xenograft model, we found that fibroblast‑derived OPN was 
involved in tumor growth and metastasis, and that this tumor growth and metastasis was significantly suppressed by 
administration of the anti‑OPN mAbs. Our findings will lead to a novel mAb‑mediated immunotherapeutic strategy 
targeting against the interaction of OPN with integrins on the tumor of ATL patients.
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Background
Adult T-cell leukemia (ATL) is caused by the Human 
T-cell leukemia virus type 1 (HTLV-1) and is a highly 
aggressive CD4+ T-cell leukemia characterized by clonal 
integration of HTLV-1 in leukemic cells [1]. ATL is clas-
sified into four subtypes: acute, lymphoma, chronic, and 
smoldering [2]. As the prognosis of ATL patients remains 
extremely poor due to resistance to conventional chemo-
therapy regimens, introduction of new therapeutic agents 
is needed [3]. Indeed, many inhibitors and monoclonal 
antibodies targeting the tumor itself have been evaluated 
[4]. ATL cell invasion/metastasis is frequently observed 
in an early phase of disease progression, notably in the 
skin as well as the liver, lung and lymph nodes [5]. Thus, 
prevention of such invasion and metastasis could be 
another therapeutic strategy to prolong the survival time.
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Cancer progression is known to be the result of com-
plex crosstalk among different cell types in the primary 
tumor and its surrounding tissues [6]. The tumor micro-
environment has a critical role in modulating and regu-
lating the invasion and subsequent metastasis of many 
cancers [7]. It has been generally accepted that the extra-
cellular matrix (ECM) formed by activated mesenchymal 
cells and secreted matricellular molecules in the tumor 
microenvironment play a critical role in tumorigenesis 
and tumor metastasis [8]. Interaction between E-selectin 
and sialyl LewisX [9, 10], between leukocyte function-
associated antigen (LFA-1) and intracellular adhesion 
molecule (ICAM)-1 [11, 12], or between OX40 and gp34 
[13], have been reported to be critical in ATL cell adhe-
sion. Binding of the CC chemokine ligand (CCL)17 and 
CCL22 with the CC chemokine receptor (CCR)4, or of 
CCL19 and CCL21 with CCR7 is critical for tissue-spe-
cific metastasis [14].
Integrins, which are a large family of heterodimeric cell 
surface adhesion receptors, consist of one of 18 α and one 
of 8 β subunits [15]. It is well established that integrins 
are involved in tumor adhesion, invasion, and metastasis 
[16]. The α4β1 and α5β1 integrins are highly expressed 
in patients with lymphoma type ATL [17–19], and β7 
integrins may be involved in gastrointestinal metasta-
sis [20]. The matricellular molecule osteopontin (OPN) 
physiologically interacts with αvβ1, αvβ3, αvβ5, and α8β1 
integrins via a classical cell-binding motif, the arginine-
glycine-aspartic acid (RGD) sequence within the OPN 
molecule, or with α9β1 and α4β1 integrins via a serine-
valine-valine-tyrosine-glycine-leucine-arginine (SVVY-
GLR) sequence within the OPN molecule [21]. It has 
been widely accepted that, upon this interaction, OPN 
regulates the development of various disorders including 
not only inflammatory and autoimmune diseases but also 
cancer development [22]. Thus, inhibition of the interac-
tion of OPN with integrins could be an effective strategy 
for anti-tumor therapy [23, 24]. There is a strong correla-
tion between the plasma OPN level and tumor burden, 
suggesting that plasma OPN could be a useful tumor 
marker in many cancer types [25]. We have reported a 
strong correlation between the OPN level and disease 
severity in ATL patients, which suggests that OPN is also 
involved in ATL development [26]. Moreover, CD68-
positive macrophages and endothelial cells within tumor 
tissues express OPN, suggesting that stromal cell-derived 
OPN could be involved in the tumorigenesis of ATL. 
McAllister et al. have reported that secretion of OPN by 
instigating breast tumors is necessary for bone-marrow 
cell activation and the subsequent outgrowth of the dis-
tant indolent tumors in mice [27, 28]. On the other hand, 
we have recently proposed that stromal cell, especially 
cancer-associated fibroblast (CAF)-derived, secreted 
OPN is involved in tumor growth and metastasis in the 
breast tumor xenograft model [29].
In this study we investigated the physiological roles of 
OPN-integrin interaction on ATL pathogenesis in  vitro 
and in vivo. In order to verify the function of mesenchy-
mal stroma-derived OPN in ATL tumorigenesis in vivo, 
we used the NOD/Shi-scid,IL-2Rgnull (NOG) mouse [30] 
that has been widely utilized for analysis of ATL and 
other tumors [31]. Subcutaneous inoculation of ATL 
cell lines into NOG mice increased the plasma level of 
OPN, which significantly correlated with invasion of the 
inoculated cells and the survival time. Most importantly, 
treatment of tumor-bearing NOG mice with anti-OPN 
monoclonal antibodies (mAbs) resulted in inhibition 
not only of tumor growth but also of tumor invasion and 
metastasis. Our combined findings would lead to a novel 
OPN mAb-mediated immunotherapeutic strategy tar-
geted towards the interaction of host stromal cell-derived 
OPN with integrins on tumor cells in ATL patients.
Results
OPN and integrin expression in tumor tissues and primary 
lymphocytes obtained from ATL patients
We first assessed the expression of OPN in lymph nodes 
obtained from ATL patients (acute type and chronic 
type) using immunohistochemical staining. As previously 
reported by Changan-Yasutan et al., we detected human 
OPN expression in CD68-positive macrophages (Fig. 1a). 
Moreover, we also detected many fibroblast activation 
protein (FAP)-positive fibroblasts, called cancer-associ-
ated fibroblasts (CAFs), within the lymph nodes of ATL 
patients (Fig. 1a). The widespread OPN staining and the 
large number of FAP-positive fibroblasts suggests that 
the majority of CAFs express OPN. Based on the OPN 
staining pattern in comparison with CD4+CD25+ lym-
phocyte staining it seemed unlikely that the ATL cells 
themselves expressed OPN (Fig. 1a). Since we have pre-
viously reported an increase in plasma OPN levels in 
ATL patients [26], we next determined if this increase 
might be due to OPN secretion by the ATL cells them-
selves, by examination of the level of OPN secreted into 
the supernatant of ATL-derived cell lines and HTLV-
I-transformed T cell lines. Unexpectedly but interest-
ingly, we found that the cell lines secreted very little 
OPN into the supernatant (Additional file 1: Figure S1). 
We also tested if these cell lines expressed OPN recep-
tors such as αvβ3, αvβ5, α4β1, and α9β1 integrins, or 
CD44std and CD44v6. FACS analysis indicated that each 
cell line expressed at least one of the OPN receptors on 
the cell surface. Further FACS analysis demonstrated that 
CD4+CD25+ T cells obtained from acute and chronic 
type ATL patients expressed α4β1, α5β1, and α9β1 inte-
grins, and CD44std and CD44v6, while the expression 















Fig. 1 OPN expression in stromal cells of lymph nodes, and Integrin and CD44 expression in primary lymphocytes from ATL patients. a Human 
OPN, CD68, FAP, CD25, and H&E stained sections of ATL lymph nodes are shown. Scale bars, 50 μm. b PBMCs were isolated from patients with acute 
(n = 2) and chronic (n = 2) type ATL. The CD4+CD25+ population was gated, and the expression of integrins and of CD44 was evaluated using a 
FACS Calibur flow cytometer. Green filled histograms indicate cells stained with mAbs to the indicated integrins or CD44 variants. Red open histograms 
represent cells stained with isotype control IgGs. Data of a representative experiment from acute type ATL (primary ATL1 in Additional file 2: Table 
S1) are shown
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of RGD motif-recognizing αvβ3 and αvβ5 integrins was 
extremely low or undetectable (Fig. 1b; Additional file 2: 
Table S1).
To address the involvement of OPN in the invasion 
process of ATL cells, we conducted an in  vitro matrigel 
invasion assay. For this assay, we chose three cell lines 
with different integrin and OPN expression patterns; the 
in  vitro HTLV-1 transformed T cell line SLB-1 (OPN+, 
αvβ3+, α4β1−, α9β1+, and CD44v6+), and two ATL-
derived cell lines TL-OmI (OPN−, αvβ3−, α4β1+, α9β1+, 
and CD44v6−) and 43Tb(−) (OPN−, αvβ3−, α4β1+, α9β1−, 
and CD44v6−). Assay of their invasive ability indicated 
that the SLB-1 cells displayed the highest invasive ability 
of the three cell lines tested (Additional file 3: Figure S2). 
To evaluate the role of OPN in the invasion process, we 
treated the cell lines with an SVVYGLR motif-recognizing 
anti-OPN mAb; this anti-OPN antibody partially but sig-
nificantly reduced the invasion of both SLB-1 and TL-OmI 
cells in vitro (Additional file 4: Figure S3). Anti-αvβ3 integ-
rin and anti-β1 integrin mAbs were also used in the assays. 
It is noteworthy that anti-αvβ3 mAb exhibited inhibitory 
effect on the invasion of SLB-1 cells, while anti-β1 mAb 
reduced the invasion of both SLB-1 and TL-OmI cells 
(Additional file 4: Figures S3). In contrast to its effect on 
cell invasion, these mAbs did not inhibit ATL cell growth 
in vitro (Additional file 5: Figure S4).
Inoculation of in vitro transformed or ATL‑derived T cell 
lines into NOG mice
To further evaluate the biological function of OPN 
in  vivo, we subcutaneously inoculated the SLB-1, TL-
OmI, and 43Tb(−) cell lines into NOG mice as described 
previously [32, 33]. The three cell lines inoculated into 
NOG mice produced visible tumors within 3  weeks 
(Fig.  2a). However, the SLB-1 tumor-bearing NOG mice 
had a poor prognosis, whereas the NOG mice inoculated 
with TL-OmI or 43Tb(−) survived longer than those 
inoculated with SLB-1 (Fig.  2b). It is noteworthy that 
the mouse OPN level in the plasma of SLB-1-inoculated 
NOG mice increased immediately after cell inoculation, 
while the increase in mouse OPN levels in the plasma of 
TL-OmI-inoculated NOG mice was only detectable at 
24 days after inoculation. Mouse OPN levels were not sig-
nificantly increased in 43Tb(−)-inoculated NOG mice up 
to 40 days after cell inoculation (Fig. 2c). Tumor-derived 
human OPN levels in plasma were negligible in compari-
son with the levels of host-derived murine OPN (data 
not shown). The data in Fig. 2c indicate that, similar to a 
previous study of human ATL patients [26], plasma OPN 
levels correlated well with poor prognosis in the xeno-
grafted NOG mice, strongly suggesting that this mouse 
model could be a useful tool for assessment of the physi-
ological role of host-derived OPN in the pathogenesis of 
ATL. Very interestingly, the number of metastatic cells 
as judged by the appearance of ATL cells in the periph-
eral blood of NOG mice (assessed by assay of the HTLV-1 
tax gene) correlated well with the plasma OPN levels 
(Fig.  2d). The level of ATL cells in the peripheral blood 
of NOG mice was higher when the mice were inoculated 
with SLB-1 cells than when they were inoculated with 
TL-OmI or 43Tb(−) cells as judged by Giemsa staining 
(Fig.  2e). Metastasis of SLB-1 cells, as judged by human 
CD4 staining of a subcutaneous tumor and of the lung, 
was also striking in the lung (Fig. 2f, g). As expected, while 
tumor cell-derived human OPN could not be detected 
in metastatic tissues (Additional file  6: Figure S5), host 
cell-derived mouse OPN was detected (Fig. 2f ). We also 
detected the large number of FAP-positive fibroblasts in 
the primary SLB-1 tumors, suggesting that the majority of 
CAFs express OPN (Fig. 2f ). In addition, OPN expression 
in the lung with metastatic SLB-1 cells was higher than 
that with metastatic TL-OmI or 43Tb(−) cells (Fig.  2g). 
These results indicated that host cell-derived OPN played 
an important role in tumor growth and metastasis.
Treatment of tumor‑bearing NOG mice with anti‑OPN 
mAbs
To further investigate the role of OPN in ATL tumorigen-
esis, we intraperitoneally administered two different anti-
OPN mAbs into TL-OmI tumor-bearing NOG mice, an 
SVVYGLR motif- and an RGD motif-recognizing mAb. 
Administration of these anti-OPN mAbs, singly or in 
combination, starting at 24 days after tumor cell inocula-
tion, significantly suppressed the level of mouse OPN in 
(See figure on next page.) 
Fig. 2 Host‑derived OPN production correlates with pathogenicity in tumor cell‑inoculated NOG mice. Six‑week‑old female NOG mice were sub‑
cutaneously inoculated with 5 × 107 SLB‑1 (n = 5), TL‑OmI (n = 5), or 43Tb(−) (n = 5) cells. a The tumor size was measured every 3–4 days and is 
expressed in cubic millimeters. Bars indicate mean values ± SEM. b Survival rate was monitored based on death of the mice. c Blood was collected 
from the tail vein for measurement of the mouse OPN level in the plasma, and d for detection of metastatic cells as quantified by the number of 
tax genes assessed using qPCR. Bars indicate mean values ± SEM. For a–d, filled squares, SLB‑1; filled circles, TL‑OmI; filled triangles, 43Tb(−). e PBMCs 
were isolated on day 20 after the indicated cell inoculation and were stained with Giemsa. Scale bars, 50 μm. f Immunohistochemical staining of 
a subcutaneous tumor from an NOG mouse 20–50 days after the indicated cell inoculation. The sections were stained with Abs to the indicated 
proteins or with H&E. Arrows indicate the positive staining of mouse OPN. Scale bars, 100 μm. g Immunohistochemical staining of the lung from an 
NOG mouse 20–50 days after the indicated cell inoculation. The sections were stained with Abs to the indicated proteins or with H&E. Scale bars, 
100 μm
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plasma (Fig.  3a). Under this experimental condition, the 
SVVYGLR motif-recognizing anti-OPN mAb signifi-
cantly inhibited tumor growth (Fig.  3b). This inhibition 
correlated well with a reduction in Ki-67-positive cells in 
the primary tumors (Fig.  3c). It is of note that this anti-
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Fig. 3 Anti‑OPN mAbs suppressed the tumor growth and metastasis of ATL cells inoculated into NOG mice. Six‑week‑old female NOG mice were 
subcutaneously inoculated with 2 × 107 TL‑OmI cells. At 24 days after cell inoculation, the indicated anti‑OPN mAbs (n = 5) or control IgG (n = 5) 
were intraperitoneally administered into the mice every 3–4 days. a Blood from the tail vein was collected for measurement of the mouse OPN level 
in the plasma. b The tumor size was measured every 3–4 days. c Immunohistochemical detection of tumor proliferation assessed by Ki‑67 staining 
on day 40 after cell inoculation. d Blood from the tail vein was collected and metastatic cells were quantified by the number of tax genes assessed 
using qPCR. e Immunohistochemical detection of tumor metastasis by CD25 staining of liver tissue on day 40. f Immunohistochemical detection of 
CAFs by FAP staining of tumor tissues on day 40. For all of a–f, bars indicate mean values ± SEM. Statistically significant differences are shown as P 
values (*P < 0.05, **P < 0.01). NS no significant difference. For a, b and d, open squares, control IgG; filled squares, OPN RGD motif‑recognizing mAb; 
open circles, OPN SVVYGLR motif‑recognizing mAb; filled circles, OPN SVVYGLR motif‑recognizing + RGD motif‑recognizing mAbs
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shown in Additional file  5: Figure  S4. The discrepancy 
between the in  vivo and in  vitro effect of this anti-OPN 
mAb led us to speculate that this anti-OPN mAb might 
indirectly inhibit tumor growth via suppression of stromal 
cell function in vivo. In addition to the inhibition of tumor 
growth in  vivo, the SVVYGLR motif-recognizing anti-
OPN mAb also suppressed the metastasis of inoculated 
ATL cells into peripheral blood (Fig.  3d) and metastasis 
to the liver (Fig. 3e) in vivo, suggesting that the SVVYGLR 
sequence in OPN is critical for regulating tumor growth 
and metastasis. We observed similar effects of the SVVY-
GLR motif-recognizing anti-OPN mAb on SLB-1-inocu-
lated NOG mice (Additional file 7: Figure S6). Since OPN 
is produced by the host cells, as shown Fig. 2c, we exam-
ined the effect of this anti-OPN mAb on host cells in the 
tumor tissue. Since there were a large number of FAP-
positive (CAF) cells in the tumor (Fig. 1a), we examined 
the effect of this antibody on the number of FAP-positive 
cells. We found that the number of FAP-positive CAFs in 
the primary tumor tissues was reduced by the SVVYGLR 
motif-recognizing anti-OPN mAb on day 40 after inocu-
lation, indicating that OPN is required for the recruitment 
of FAP-positive fibroblasts to the tumor (Fig. 3f ). On the 
other hand, the RGD motif-recognizing anti-OPN mAb 
was less effective than the SVVYGLR motif-recognizing 
anti-OPN mAb, emphasizing that targeting the SVVY-
GLR sequence rather than the RGD sequence in OPN is 
critical for controlling tumor development in this mouse 
model. However, interestingly, co-administration of the 
two anti-OPN mAbs exhibited cooperative effects on 
tumor growth (Fig.  3a–f). The combined data indicated 
that OPN regulated primary tumor growth by the recruit-
ment of CAFs and by mediating tumor metastasis via its 
binding to α9β1 and/or α4β1 integrins. 
Co‑inoculation of an ATL‑derived cell line with mouse 
embryonic fibroblasts
To further investigate the biological role of CAF-derived 
OPN on ATL tumorigenesis and tumor metastasis 
in vivo, we subcutaneously inoculated mouse embryonic 
fibroblasts (MEFs) isolated from wild-type (WT) or OPN 
knockout (KO) mice [34] together with TL-OmI cells 
into the NOG mice. The mice co-inoculated with OPN 
KO MEFs displayed a significant increase in survival rela-
tive to those co-inoculated with WT MEFs (Fig. 4a). The 
absence of MEFs further improved the survival rate of 
TL-OmI-inoculated mice (Fig.  4a). Tumor growth was 
also evaluated by measuring the size of subcutaneous 
tumors. As shown in Fig.  4b, significantly lower tumor 
growth was observed in TL-OmI-injected mice co-inoc-
ulated with OPN-deficient MEFs compared with those 
co-inoculated with WT MEFs. Tumor growth was even 
lower in mice inoculated with TL-OmI alone. Inoculation 
of WT or OPN-deficient MEFs alone did not induced 
tumor formation at the inoculation sites (Fig.  4b). 
Although the plasma OPN level in TL-OmI/OPN KO 
MEF-inoculated mice was lower than that in TL-OmI/
WT MEF-inoculated mice, it was still significantly higher 
than that in mice inoculated with TL-OmI alone, indi-
cating that other factor(s) are involved in OPN produc-
tion (Fig.  4c). Metastasis of inoculated cells correlated 
well with tumor growth (Fig.  4d). We further examined 
if the OPN derived from MEFs is involved in metastasis 
of the tumor cells. Metastasis to the liver was evaluated 
on day 40 after cell inoculation. Consistent with the data 
in Fig. 4d, the number of metastatic cells as assessed by 
immunohistochemical staining of CD4 in the liver was 
significantly increased in TL-OmI/WT MEF-inoculated 
mice compared with TL-OmI-inoculated mice, and the 
absence of OPN in the co-inoculated MEFs resulted in 
a lower number of tumor cells in the liver (Fig. 4e). We 
observed similar effects of the MEFs on tumor growth of 
43Tb(−)-inoculated NOG mice (Additional file 8: Figure 
S7a). We detected metastatic cells in 43Tb(−)/MEF-inoc-
ulated mice, but the number of metastatic 43Tb(−) cells 
was lower than that in mice inoculated with SLB-1 alone 
or TL-OmI alone (Additional file  8: Figure S7b). Under 
this condition, the mouse OPN level in the plasma of 
43Tb(−)/MEF-inoculated NOG mice was not increased 
up to 40 days after cell inoculation (data not shown), sug-
gesting that the level of host-derived OPN in plasma is 
dependent on the number of metastatic cells. These com-
bined data strongly suggested that the fibroblasts could 
be involved not only in tumor growth but also in tumor 
metastasis of ATL.
Discussion
Cancer-related mortality is largely caused by tumor 
metastasis, therefore an understanding of the molecular 
mechanisms of metastasis is needed to develop a thera-
peutic anti-tumor strategy. ECM is a critical component 
of the microenvironment for tumor metastasis, and the 
matricellular molecule OPN plays an important role in 
this process. Based on our previous findings in a breast 
tumor model [29], the present study aimed to understand 
the biological function of OPN in the pathogenesis of 
ATL. Our present study provides new evidence that OPN 
could be involved in the tumorigenesis and tumor metas-
tasis of ATL in a xenograft murine model. Furthermore, 
we designed and performed experiments using a novel 
therapeutic strategy that employed SVVYGLR motif- and 
RGD motif-recognizing anti-OPN mAbs in NOG mice. 
We demonstrate for the first time that interaction of 
host-derived OPN with tumor-derived integrins could be 
an attractive molecular target for mAb-mediated immu-
notherapy in ATL.
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Fig. 4 OPN produced by MEFs promotes the tumor growth and metastasis of ATL cells inoculated into NOG mice. Six‑week‑old female NOG mice 
were subcutaneously inoculated with TL‑OmI cells alone (n = 5) or together with either WT MEFs (n = 5) or OPN KO MEFs (n = 5) (1 × 107 cells 
per cell type). WT‑MEFs (n = 3) or OPN KO MEFs (n = 3) only were also inoculated as negative controls. a Survival rate was monitored by death of 
the mice. b The tumor size was measured every 3–4 days. c Blood was collected from the tail vein for measurement of the mouse OPN level in the 
plasma and for d detection of metastatic cells as quantified by the number of tax genes assessed using qPCR. e Metastasis to the liver was evalu‑
ated by immunohistochemical staining of human CD4 on day 40. For all of b–e, bars indicate mean values ± SEM. Statistically significant differences 
are shown with P value (*P < 0.05, **P < 0.01). For a–d, filled square, TL‑OmI + WT MEFs; open square, TL‑OmI + OPN KO MEFs; filled circle, TL‑OmI 
only; open circle, WT MEFs; filled triangle, OPN KO MEFs
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The relevance of elevated OPN production to human 
cancer pathogenesis has been shown [25]. However, 
the role of host-derived OPN in cancer pathogenesis 
has been unclear. In the case of ATL, we have previ-
ously reported that the prognosis was inversely cor-
related with the plasma OPN level, suggesting that 
OPN is also involved in ATL pathogenesis [26]. In this 
study we unexpectedly found ATL cell lines secreted 
very little OPN into the supernatant (Additional file 1: 
Figure S1). Among HTLV-I-infected cell lines, HTLV-I 
Tax protein is expressed in SLB-1 cells but not in TL-
OmI cells and 43Tb(−) cells [35, 36]. Since the Tax 
protein activates OPN transcription mediated by a 
distal AP-1 site in the OPN promoter [37], it is likely 
that Tax expression and OPN production are corre-
lated. We also found that NOG mice that were subcu-
taneously inoculated with ATL cell lines exhibited an 
increase in OPN levels in plasma (Fig. 2c). Very inter-
estingly, the relationship between host-derived OPN 
production, survival time, and cell metastasis in the 
NOG mice was similar to that in ATL patients. The 
results of the cell invasion assay would be at least in 
part explained by the migration activity of each cell 
line in vitro (Additional file 3: Figure S2). It is of note 
that we found the three cell lines we used in this study 
had different integrin expression pattern (Additional 
file 2: Table S1). As shown in Additional file 4: Figure 
S3, the invasion process partially depends on the αvβ3 
integrin and β1 integrin. Tuck et  al. reported that 
more aggressive breast tumor cells preferentially used 
αvβ3 integrin but not αvβ5 or β1 integrins to respond 
to OPN [38], and we reported that α9β1 integrin is 
also involved in breast tumor metastasis [29]. In addi-
tion, OPN promotes tumor growth via αvβ3 integrin 
[39], or via α9β1 integrin [40] by distinct signaling 
pathways. These data suggest that the integrin expres-
sion pattern could be one of critical factors to deter-
mine the frequency of metastasis and tumor growth 
in ATL pathogenesis. The combined data suggest that 
the regulation of metastasis is critical for improving 
prognosis, and that host cell-derived OPN is involved 
in the metastasis observed in our xenograft model. 
Therefore, very importantly, this study has provided 
evidence that this NOG mouse model should be use-
ful for evaluation of the biological involvement of 
not only OPN but also other associated genes in ATL 
pathogenesis in  vivo. Besides OPN, other matricel-
lular proteins that could interact with integrins such 
as tenascin-C [41], CCN-1 [42], or periostin [43] have 
not been reported in ATL patients, thus it will also be 
interesting to investigate a role of these molecules in 
patient samples and this NOG mouse model. On the 
other hand, we have previously reported an increase 
in plasma soluble CD44 (sCD44) levels in correla-
tion with OPN in patient samples [26]. We found that 
HTLV-I-transformed cell lines and primary ATL cells 
express CD44 (Fig.  1b; Additional file  2: Table S1), 
which could be supported with an evidence that CD44 
promoter is activated by HTLV-I Tax protein via non-
canonical NF-κB pathway [44]. There is a strong cor-
relation between the plasma sCD44 level and tumor 
development, suggesting that plasma sCD44 could be 
another useful tumor marker in many cancer types 
[45]. It is of great interest to investigate the relation-
ship between OPN and sCD44 in ATL pathogenesis in 
our xenograft model.
The tumor microenvironment consists of a wide 
variety of non-tumor cell types such as fibroblasts, 
endothelial cells, and immune cells including mac-
rophages [46]. Fibroblasts are the most abundant 
mesenchymal stroma cells (MSCs) within most car-
cinomas, and are widely regarded as CAFs that are 
definitely crucial for cancer development [47, 48]. 
Activated CAFs express molecules that could be use-
ful as prognostic markers [49]. We previously found 
that OPN can be produced by activated fibroblasts 
in  vivo, and we observed that these fibroblasts were 
induced to produce OPN either by direct interaction 
with tumor cells or by soluble factors derived from the 
tumor cells in vitro [29]. Indeed, in the present study 
we found that the number of FAP-positive cells was 
reduced by anti-OPN mAbs in primary tumor tissues, 
indicating that recruitment of CAFs are regulated via 
host-derived OPN (Fig.  3f ). Moreover, tumor growth 
and metastasis were augmented by the addition of 
exogenous WT MEFs but not by OPN KO MEFs 
(Fig.  4), strongly suggesting the involvement of stro-
mal OPN in ATL pathogenesis in vivo. With regard to 
the mechanisms of augmented OPN production, our 
preliminary data suggested that OPN production by 
fibroblasts was induced by direct interaction with ATL 
cells or with soluble factors derived from ATL cells. 
It has been reported that OPN production is induced 
by stimulation of a number of cell types with IFN-γ 
[50], IL-1 [51], TGF-β [52], or TNF-α [53]. However, 
we failed to detect the production of these cytokines 
by the ATL cells examined in this study, suggesting 
that other molecule(s) might be involved in ATL-asso-
ciated OPN production. It is also possible that ATL 
cells could be induced to produce these cytokines by 
interacting with stromal cells in vivo. We are currently 
investigating how fibroblasts are induced to produce 
OPN in ATL pathogenesis. On the other hand, we have 
observed strong OPN expression in CD68-positive 
macrophages [26] as also shown in Fig.  1, suggesting 
that macrophages are involved in ATL pathogenesis 
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through the production of OPN. Tumor-associated 
macrophages (TAMs) have been considered as criti-
cal stromal cells in the tumor microenvironment [54], 
and OPN is indeed up-regulated in TAMs [55, 56]. 
Moreover, an increased number of TAMs was strongly 
associated with shortened survival in patients with 
classical Hodgkin’s lymphoma and provides a new 
biomarker for risk stratification [57]. Although NOG 
mice have severe and multiple immune dysfunctions, 
phagocytic activity of macrophages is functionally 
retained [58]. In addition, several growth factors such 
as PDGF, EGF, and FGF produced by TAMs are able 
to activate fibroblasts [59]. Thus, the anti-OPN mAbs 
might reduce recruitment and activation of fibroblasts 
into primary tumor via suppressing OPN produced 
by TAMs. Therefore it remains to be investigated 
whether activated macrophages are involved in ATL 
pathogenesis. It will be interesting to evaluate the 
effects of macrophage-depleting reagents (e.g. dichlo-
romethylene diphosphonate-containing liposomes) on 
ATL progression in our mouse model.
Reducing metastasis should be a major strategy to 
cure cancer and improve prognosis. Previous studies 
support the idea that OPN can act as a potential tar-
get for cancer therapy [60, 61]. In this study we inves-
tigated the effects of two different mAbs against OPN 
in an NOG mouse model of ATL and found that these 
two mAbs exerted distinct effects on the growth and 
metastasis of ATL cells. Since α9β1 and α4β1 integ-
rins, the target of the SVVYGLR motif-recognizing 
mAb, are strongly expressed in TL-OmI cells but 
the αvβ3 integrin, which is the target of RGD motif-
recognizing mAb, is not, it is likely that the distinct 
Ab effects observed are due to the expression level 
of these integrins. However, co-administration of 
the two mAbs exerted cooperative effects on tumor 
growth. OPN is known to be cleaved by cellular pro-
teases, especially thrombin-cleaved N-half OPN 
exposes SVVYGLR-motif, which is recognized by 
α9β1 and α4β1 integrins, while full-length OPN is rec-
ognized by αvβ1, αvβ3, αvβ5, α5β1, and α8β1 integrins 
[21]. The RGD motif-recognizing mAb could reduce 
the full-length OPN (Fig.  3a) that results in reducing 
thrombin-cleaved N-half OPN, which is recognized 
by the SVVYGLR motif-recognizing mAb. It would 
be one of the possible mechanisms of the cooperative 
effects by co-administration on tumor growth. Fur-
ther studies are required to understand the molecular 
mechanisms of the synergistic effects of these mAbs. 
However, this study has provided the first evidence 
that anti-OPN mAbs can reduce tumor growth and 
metastasis mainly by suppressing host cell-derived 
OPN production (Fig.  3). These mAbs might also 
reduce the invasion and metastasis of ATL cells via 
suppression of the tumor-derived OPN, as specu-
lated based on the in vitro invasion assay (Additional 
file  4: Figure S3). On the other hand, with regard to 
the receptors for OPN, we detected strong expres-
sion of α9β1 integrin, as well as of α4β1, α5β1 and β7 
integrins, while the expression of αvβ3 and αvβ5 inte-
grins that interact with OPN via the RGD motif was 
much lower or undetectable on human primary ATL 
cells. We recently showed that the α9β1 integrin in 
tumors regulates not only breast tumor growth and 
metastasis but also OPN production from CAFs in 
breast tumor xenograft models [29]. In that study we 
first developed and used an anti-α9β1 integrin mAb 
that could inhibit the binding of the synthetic peptide, 
SVVYGLR. This anti-α9β1 integrin mAb suppressed 
tumor growth and metastasis in the breast tumor 
model. Since we detected the expression of α9β1 inte-
grin in primary ATL cells (Fig.  1), it may be of value 
to evaluate the anti-tumor activity of this anti-α9β1 
integrin mAb in the ATL xenograft model. In addi-
tion, CD44v6 could be another interesting target for 
ATL therapy, because we also detected the expression 
of CD44v6 in primary ATL cells (Fig.  1b), similar to 
other cancer types [62]. Binding of CD44v6 to OPN 
is dependent on β1 integrin but independent of RGD-
motif to promote cell motility and chemotaxis [63], 
thus combination of β1 integrin and CD44v6 mAbs 
would be an attractive strategy on cancer treatment. 
Currently anti-CD44v6 mAb bivatuzumab conjugated 
with the maytansine derivative DM1 has been evalu-
ated [64]. The combined data suggest that mAb-medi-
ated immunotherapy targeting the molecules involved 
in invasion and metastasis would be a promising ther-
apeutic approach for effective management of ATL. 
It is well known that skin metastasis of ATL tumors 
depends at least in part on CCR4 preference [65]. 
Indeed, the anti-CCR4 mAb mogamulizumab, which 
showed significant anti-tumor activity against ATL 
cells in the NOG mice via enhanced antibody-depend-
ent cell-mediated cytotoxicity (ADCC) [66], has been 
developed and subsequently approved for the treat-
ment of relapsed or refractory ATL in Japan [67]. 
Thus, understanding how chemokines and chemokine 
receptors are involved in ATL tumor metastasis 
should be important for planning an effective thera-
peutic strategy. Whereas CCR4 molecules are pre-
dominantly expressed in T cells, CCR5 molecules 
are expressed on CAFs and TAMs [14]. Interestingly, 
Mi et  al. reported that OPN induced the production 
of the chemokine CCL5 from MSCs [68]. Moreover, 
they hypothesized that tumor-derived but not host-
derived OPN could promote tumor progression via 
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the transformation of MSCs into CAFs, and through 
increased MSC migration to metastatic sites such as 
lung and liver. In support of this observation, Wu et al. 
reported that a deficiency of the CCL3 or CCR5 genes 
strongly reduced the number of metastatic foci in the 
lung in a murine renal cell carcinoma model [69]. The 
role of the association of not only tumor-derived OPN 
but also of host-derived OPN with chemokines in 
ATL pathogenesis remains to be further investigated. 
An evaluation of chemokine or chemokine receptor 
induction by OPN is under way.
Conclusions
In this study, we have shown that a xenograft NOG mice 
model can be a useful system to assess the physiological 
role of OPN in ATL pathogenesis. Using this xenograft 
assay, we found that stromal cell-derived but not tumor-
derived OPN levels were increased during the course of 
tumor development. We noted that plasma OPN levels 
correlated well with poor prognosis and the number of 
metastatic cells. Furthermore, we found that fibroblast-
derived OPN was involved in tumor growth and metas-
tasis, which was significantly suppressed by the anti-OPN 
mAbs. Again, we emphasize that this study contributes to 
the understanding of physiological OPN involvement in 
ATL pathogenesis. Based on our new findings, we here 
propose the use of anti-OPN mAb as a novel therapeu-
tic agent targeting this matricellular molecule in the host 
ECM for the treatment of ATL.
Methods
Animals
NOG mice [30] were obtained from the Central Institute 
for Experimental Animals (Kawasaki, Japan). Wild-type 
(WT) BALB/c mice were purchased from Japan SLC 
(Hamamatsu, Japan). OPN knockout (KO) mice were 
generated [34] and backcrossed at least 10 generations to 
BALB/c mice. All mice were maintained under specific-
pathogen-free conditions in the Laboratory of Animal 
Experiments, Institute for Genetic Medicine, Hokkaido 
University.
Cells
The HTLV-I-transformed T cell lines, C5/MJ, HUT-
102, MT-2, MT-4, and SLB-1, and the ATL-derived cell 
lines, KK1, KOB, LM-Y1, ST1, TL-OmI, and 43Tb(−), 
were grown in RPMI-1640 medium supplemented with 
10  % heat-inactivated fetal bovine serum (FBS), penicil-
lin (100 units/ml), and streptomycin (100 μg/ml). Recom-
binant human interleukin (IL)-2 (0.5  nM) was added to 
the culture of KK1, KOB, and LM-Y1. Mouse embryonic 
fibroblasts (MEFs) were isolated from E13.5 embryos of 
WT BALB/c or OPN KO mice. The isolated cells were 
treated with trypsin-EDTA at 37 °C for 30 min, and were 
cultured in D-MEM supplemented with 10 % heat-inac-
tivated FBS, penicillin (100 units/ml), and streptomycin 
(100 μg/ml).
Anti‑OPN mAbs
Both anti-OPN mAbs were obtained by immunizing mice 
with the synthetic peptide VDVPNGRGDSLAYGLR. 
This sequence is located in the internal sequence of 
murine OPN.
Fluorescence‑activated cell sorting (FACS) analysis
The expression of human CD4, CD8, αvβ3, αvβ5, α4β1, 
α5β1, α9β1, and β7 integrins as well as the stand-
ard and variant form of CD44 (CD44std and CD44v6, 
respectively) in human cell lines were examined by 
using a FACS Calibur flow cytometer (BD Biosciences). 
Primary antibodies were purchased as follows; CD4 
(MT310; DAKO), CD8 (DK25; DAKO), αvβ3 integrin 
(LM609; Millipore), αvβ5 integrin (15F11; Millipore), 
α4 integrin (P1H4; Millipore), α5 integrin (IIA1; BD 
Pharmingen), α9β1 integrin (Y9A2; Millipore), β1 inte-
grin (HUTS-4; Millipore), β1 integrin (P4C10; CHEMI-
CON INTERNATIONAL), β7 integrin (473207; R&D 
Systems, Inc., USA), CD44 std (SFF-2; Bender MedSys-
tems), CD44v3-10 (2C5; R&D Systems, Inc., USA), 
CD44v6 (2F10; R&D Systems, Inc., USA), and Nega-
tive control IgG1, IgG2a, and IgG2b (Millipore). Pri-
mary ATL lymphocytes from patients with acute and 
chronic ATL were isolated and analyzed at Nagasaki 
University Hospital. This study was approved by the 
Ethics Committees of Nagasaki University Hospital. 
In the CD4+CD25+ fraction, the expression of αvβ3, 
αvβ5, α4β1, α5β1, α9β1, and β7 integrins, as well as of 
CD44std and CD44v6 was analyzed using flow cytome-
try. Background-corrected mean fluorescence intensity 
(MFI) was determined for each cell type.
Enzyme‑linked immunosorbent assay (ELISA)
Blood was collected from the mouse tail with heparin, 
and the plasma was isolated to measure the amount of 
mouse OPN. The level of mouse OPN in mouse plasma 
and of human OPN in the supernatant of human cell lines 
was measured using a Mouse or Human OPN ELISA kit 
(R&D Systems, Inc., USA), respectively.
In vitro cell invasion assay
This assay was performed using a BD BioCoat 
Matrigel Invasion Chamber (BD Biosciences) accord-
ing to the protocol provided by the manufacturer. 
Briefly, the lower wells were filled with RPMI-1640 
medium without supplements. Cells (SLB-1, TL-OmI, 
and 43Tb(−)) were seeded at a density of 1 × 105 cells 
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in serum-free RPMI-1640 medium in the invasion 
chamber containing the matrigel membrane and were 
allowed to settle for 3 h at 37 °C. RPMI-1640 medium 
supplemented with 10  % heat-inactivated FBS was 
added to the lower compartment of the invasion 
chamber. The chambers were incubated in the pres-
ence of 50 μg/ml of anti-OPN mAb, anti-αvβ3 integrin 
mAb, anti-β1 integrin mAb or control IgG for 8–24 h 
at 37  °C. The invading cells appeared at the lower 
surface of the membrane. The upper surface of the 
membrane was scrubbed and the absence of cells at 
the upper surface was confirmed. After the cells were 
fixed with methyl alcohol and stained with Giemsa, 
the membrane was covered with immersion oil and a 
cover slip, and the cells were randomly counted under 
a microscope.
In vitro cell proliferation assay
Cells (SLB-1 and TL-OmI) were seeded at a density of 
1 ×  105 cells in the presence of 50  μg/ml of anti-OPN 
mAb, anti-αvβ3 integrin mAb, anti-β1 integrin mAb or 
control IgG for 72 h at 37 °C. The cells were further incu-
bated with the Cell Proliferation Reagent WST-1 (Roche) 
for 2 h at 37 °C. The absorbance of the samples was meas-
ured at 450 and 550 nm (reference wave length) using a 
microplate reader.
Quantitative PCR analysis of the HTLV‑I tax gene
Total genomic DNA was extracted from PBMCs derived 
from NOG mice using the DNeasy Blood & Tissue Kit 
(QIAGEN) according to the protocol provided by the 
manufacturer. Quantitative PCR (qPCR) was performed 
using the LightCycler FastStart DNA MasterPLUS Hybrid-
ization Probes (Roche Applied Science, Germany). The 
PCR condition was as follows; 40 cycles of 94 °C for 30 s., 
60 °C for 10 s., and 72 °C for 15 s. The primer sequences 
were as follows: forward primer, 5′-CCCGAAGACT 
GTTTGCCCA-3′, and reverse primer, 5′-GGAAATCAT 
AGGCGTGCCATC-3′. Hybridization probe sequences 
were as follows: the fluorescein isothiocyanate (FITC)-
labeled probe was 5′-ACGGCCTCCTTCCGTTCC-3′, 
and the LC Red 640-labeled probe was 5′-TCAACCCT 
CACCACTCCAGGCCTTATTTGGA-3′. To construct a 
standard curve, a tax DNA plasmid was serially 10-fold-
diluted from 2 × 104 to 2 × 101 copies/μl.
Histological and cytological staining
Blood smear slides were fixed with methyl alcohol and 
dried for Giemsa staining. Lung, liver, or tumor was 
excised from NOG mice inoculated with or without 
cell lines. Part of the excised organs were fixed with 
dry-ice acetone, embedded in Tissue-Tek OCT com-
pound (Sakura Finetechnical Co. Ltd., Tokyo, Japan), 
and stored at −80 °C until use. Frozen sections of the 
organs were prepared using a Cryostat and were fixed 
in acetone at room temperature for 20  min. The rest 
of the excised organs were fixed with 4  % paraform-
aldehyde for H&E staining. These organs were also 
stained with antibodies against human OPN (O-17, 
IBL, Gunma, Japan), human CD4 (MT310, DAKO), 
human IL-2Rα (CD25) (R&D Systems, Inc., Minneap-
olis), mouse OPN (O-17, IBL, Gunma, Japan), human 
Ki-67 (Abcam), and mouse fibroblast activation pro-
tein (FAP) (rabbit polyclonal, Abcam). Tissue sam-
ples from patients with ATL were analyzed at Tohoku 
University Hospital. This study was approved by the 
Ethics Committees of Tohoku University Hospital. 
The tissues were also stained with H&E, human OPN 
(MPIIIB101, DSHB), human FAP (rabbit polyclonal, 
Abcam), human CD25 (4C9, Roche), and a mac-
rophage marker CD68 (PG-M1, DAKO) as described 
above.
Tumor xenograft model
SLB-1, TL-OmI, and 43Tb(−) cells were washed twice 
with serum-free RPMI-1640 medium. These cells were 
re-suspended in serum-free RPMI-1640 medium and 
inoculated subcutaneously into the NOG mice at a 
density of 1–5 × 107 cells per mouse. For therapeutic 
experiments, 400  μg of anti-OPN (SVVYGLR) mAb, 
400  μg of anti-OPN (RGD) mAb, 200  μg of each anti-
OPN (SVVYGLR) mAb and anti-OPN (RGD) mAb for 
co-administration, or 400  μg of isotype-matched con-
trol IgG were intraperitoneally injected into NOG mice 
twice a week from day 24 (TL-OmI) or day 3 (SLB-1) 
after cell inoculation. For co-inoculation experiments, 
fibroblasts from WT BALB/c or OPN KO mice were 
subcutaneously inoculated with or without TL-OmI 
cells or 43Tb(−) cells at a ratio of 1:1. The tumor size 
was measured and determined using the formula (L × 
W2)/2 (L; length, W; width). Statistically significant dif-
ferences between mAb- and control IgG-treated mice 
were calculated using Student’s t-test and are indicated 
as P values. Differences of P <0.05 were considered sta-
tistically significant. All experiments were approved 
and performed in accordance with the guidelines of the 
Committee of Ethics on Animal Experiments in Hok-
kaido University.
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Additional files
Additional file 1: Figure S1. OPN secretion into the supernatant by 
human T‑cell lines. The indicated human T cell lines (1 × 106 cells per line) 
were cultured for 24 h at 37 °C. The supernatant was then harvested for 
measurement of human osteopontin (OPN) using ELISA kits. Bars indicate 
mean values ± SEM. Data are representative of three independent 
experiments.
Additional file 2: Table S1. Integrins and CD44 expression on T cell lines 
and primary cells associated with ATL.
Additional file 3: Figure S2. Invasion of HTLV‑I‑infected or ATL‑derived 
T cell lines in vitro. The cells (SLB‑1, TL‑OmI, or 43Tb(−)) were seeded at a 
density of 1 × 105 cells in the upper part of a matrigel transwell, in RPMI‑
1640 supplemented with 10 % heat‑inactivated FBS. The cells were then 
placed on top of a lower well, which was filled with RPMI‑1640 without 
supplements. Cells that had migrated on or through the matrigel were 
fixed with methyl alcohol for H&E staining and were counted at 24 h after 
seeding. Bars indicate mean values ± SEM. Data are representative of 
three independent experiments.
Additional file 4: Figure S3. Inhibitory effects of an anti‑OPN Ab on 
invasion of HTLV‑I‑infected or ATL‑derived T cell lines in vitro. The cells 
(SLB‑1 and TL‑OmI) were seeded at a density of 1 × 105 cells in the upper 
part of a matrigel transwell and were then placed on top of the lower 
wells. Anti‑OPN mAb (SVVYGLR motif‑recognizing), anti‑αvβ3 mAb, 
anti‑β1 mAb or control IgG were added at a concentration of 50 μg/ml, 
and the cells were cultured for 8–24 h at 37 °C. Cells that had migrated 
on or through the matrigel were fixed with methyl alcohol for Giemsa 
staining and were counted at 24 h after seeding. Scale bars, 100 μm. 
Bars indicate mean values ± SEM. Statistically significant differences are 
shown as P value (*P < 0.05, **P < 0.01). Data are representative of three 
independent experiments.
Additional file 5: Figure S4. Effects of the SVVYGLR motif‑recognizing 
anti‑OPN Ab on the proliferation of HTLV‑I‑infected or ATL‑derived T cell 
lines in vitro. The cells (SLB‑1, TL‑OmI) were seeded at a density of 1 × 105 
cells in the presence of 50 μg/ml of an anti‑OPN mAb (SVVYGLR motif‑
recognizing), anti‑αvβ3 mAb, anti‑β1 mAb or control IgG in a 96‑well 
plate, and were cultured for 72 h at 37 °C. The cells were then further 
incubated with the Cell Proliferation Reagent WST‑1 (Roche) for 2 h at 
37 °C. The absorbance of the samples was measured at 450 and 550 nm 
(reference wave length) using a microplate reader. Bars indicate mean 
values ± SEM. N.S.; no significant difference. Data are representative of 
three independent experiments.
Additional file 6: Figure S5. Immunohistological staining of a subcuta‑
neous tumor and of the lung from an NOG mouse. Immunohistochemical 
staining of a subcutaneous tumor and of the lung from an NOG mouse 
20 days after subcutaneous inoculation of SLB‑1 cells. The sections were 
stained with Ab to the human OPN.
Additional file 7: Figure S6. Anti‑OPN mAb suppressed the tumor 
growth and metastasis of SLB‑1 cells inoculated into NOG mice. Six‑week‑
old female NOG mice were subcutaneously inoculated with 2 × 107 
SLB‑1 cells. At 3 days after cell inoculation, the indicated anti‑OPN mAbs 
(n = 3) or control IgG (n = 3) were intraperitoneally administered into 
the mice every 3–4 days. (A) Blood from the tail vein was collected for 
measurement of the mouse OPN level in the plasma. (B) The tumor size 
was measured every 3–4 days. (C) Blood from the tail vein was collected 
and metastatic cells were quantified by the number of tax genes assessed 
using qPCR. (D) Immunohistochemical detection of tumor metastasis by 
CD4 staining of lung tissue on day 20. For all of (A) to (D), bars indicate 
mean values ± SEM. Statistically significant differences are shown as P 
values (*, P < 0.05). For (A)–(C), open squares, control IgG; open circles, 
OPN SVVYGLR motif‑recognizing mAb.
Additional file 8: Figure S7. OPN produced by MEFs promotes the 
tumor growth and metastasis of 43Tb(−) cells inoculated into NOG mice. 
Six‑week‑old female NOG mice were subcutaneously inoculated with 
43Tb(−) cells alone (n = 3) or together with either WT MEFs (n = 3) or 
OPN KO MEFs (n = 3) (1 × 107 cells per cell type). WT‑MEFs (n = 1) or OPN 
KO MEFs (n = 1) only were also inoculated as negative controls. (A) The 
tumor size was measured every 3–4 days. (B) Blood was collected from 
the tail vein for detection of metastatic cells as quantified by the number 
of tax genes assessed using qPCR. For (A) and (B), bars indicate mean 
values ± SEM. Statistically significant differences are shown with P value 
(*P < 0.05, **P < 0.01). For (A) and (B), filled square, 43Tb(−) + WT MEFs; 
open square, 43Tb(−) + OPN KO MEFs; filled circle, 43Tb(−) only; open 
circle, WT MEFs; filled triangle, OPN KO MEFs.
Page 14 of 15Maeda et al. Retrovirology  (2015) 12:99 
Received: 12 June 2015   Accepted: 12 November 2015
References
 1. Ishitsuka K, Tamura K. Human T‑cell leukaemia virus type I and adult T‑cell 
leukaemia‑lymphoma. Lancet Oncol. 2014;15:e517–26.
 2. Shimoyama M. Diagnostic criteria and classification of clinical subtypes 
of adult T‑cell leukaemia‑lymphoma: a report from the Lymphoma Study 
Group (1984‑87). Br J Haematol. 1991;79:428–37.
 3. Katsuya H, Yamanaka T, Ishitsuka K, Utsunomiya A, Sasaki H, Hanada S, 
et al. Prognostic index for acute‑ and lymphoma‑type adult T‑cell leuke‑
mia/lymphoma. J Clin Oncol. 2012;30:1635–40.
 4. Morris JC, Waldmann TA. Antibody‑based therapy of leukaemia. Expert 
Rev Mol Med. 2009;11:e29.
 5. Yamaguchi T, Ohshima K, Karube K, Tutiya T, Kawano R, Suefuji H, et al. 
Clinicopathological features of cutaneous lesions of adult T‑cell leukae‑
mia/lymphoma. Br J Dermatol. 2005;152:76–81.
 6. Valastyan S, Weinberg RA. Tumor Metastasis: molecular insights and 
evolving paradigms. Cell. 2011;147:275–92.
 7. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat 
Rev Cancer. 2009;9:239–52.
 8. Chong HC, Tan CK, Huang RL, Tan NS. Matricellular proteins: a sticky affair 
with cancers. J Oncol. 2012;2012:351089.
 9. Ishikawa T, Imura A, Tanaka K, Shirane H, Okuma M, Uchiyama T. E‑selectin 
and vascular cell adhesion molecule‑1 mediate adult T‑cell leukemia cell 
adhesion to endothelial cells. Blood. 1993;82:1590–8.
 10. Furukawa Y, Tara M, Ohmori K, Kannagi R. Variant type of sialyl Lewis X 
antigen expressed on adult T cell leukemia cells is associated with skin 
involvement. Cancer Res. 1994;54:6533–8.
 11. Tanaka Y, Fukudome K, Hayashi M, Takagi S, Yoshie O. Induction of ICAM‑1 
and LFA‑3 by Tax1 of human T‑cell leukemia virus type 1 and mechanism 
of down‑regulation of ICAM‑1 or LFA‑1 in adult‑T‑cell‑leukemia cell lines. 
Int J Cancer. 1995;60:554–61.
 12. Tanaka Y, Mine S, Figdor CG, Wake A, Hirano H, Tsukada J, et al. 
Constitutive chemokine production results in activation of leukocyte 
function‑associated antigen‑1 on adult T‑cell leukemia cells. Blood. 
1998;91:3909–19.
 13. Imura A, Hori T, Imada K, Ishikawa T, Tanaka Y, Maeda M, et al. The human 
OX40/gp34 system directly mediates adhesion of activated T cells to 
vascular endothelial cells. J Exp Med. 1996;183:2185–95.
 14. Mukaida N, Baba T. Chemokines in tumor development and progression. 
Exp Cell Res. 2012;318:95–102.
 15. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 
2002;110:673–87.
 16. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications 
and therapeutic opportunities. Nat Rev Cancer. 2010;10:9–22.
 17. Dhawan S, Weeks BS, Abbasi F, Gralnick HR, Notkins AL, Klotman ME, et al. 
Increased expression of α4β1 and α5β1 integrins on HTLV‑I‑infected 
lymphocytes. Virology. 1993;197:778–81.
 18. Tanaka Y, Wake A, Horgan KJ, Murakami S, Aso M, Saito K, et al. Distinct 
phenotype of leukemic T cells with various tissue tropisms. J Immunol. 
1997;158:3822–9.
 19. Hasegawa H, Nomura T, Kishimoto K, Yanagisawa K, Fujita S. SFA‑1/PETA‑3 
(CD151), a member of the transmembrane 4 superfamily, associates 
preferentially with α5β1 integrin and regulates adhesion of human T 
cell leukemia virus type 1‑infected T cells to fibronectin. J Immunol. 
1998;161:3087–95.
 20. Chen H, Hori T, Maeda M, Uchiyama T. Identification of an adhesion mol‑
ecule expressed on adult T cell leukemia cells derived from a patient with 
gastrointestinal involvement: implication for a possible role of integrin 
β7 in leukemic cell infiltration into intestinal mucosa. J Clin Immunol. 
1999;19:186–93.
 21. Uede T. Osteopontin, intrinsic tissue regulator of intractable inflammatory 
diseases. Pathol Int. 2011;61:265–80.
 22. Bandopadhyay M, Bulbule A, Butti R, Chakraborty G, Ghorpade P, Ghosh 
P, et al. Osteopontin as a therapeutic target for cancer. Expert Opin Ther 
Targets. 2014;18:883–95.
 23. Rangaswami H, Bulbule A, Kundu GC. Osteopontin: role in cell signaling 
and cancer progression. Trends Cell Biol. 2006;16:79–87.
 24. Wai PY, Kuo PC. Osteopontin: regulation in tumor metastasis. Cancer 
Metastasis Rev. 2008;27:103–18.
 25. Weber GF, Lett GS, Haubein NC. Osteopontin is a marker for cancer aggres‑
siveness and patient survival. Br J Cancer. 2010;103:861–9.
 26. Chagan‑Yasutan H, Tsukasaki K, Takahashi Y, Oguma S, Harigae H, 
Ishii N, et al. Involvement of osteopontin and its signaling molecule 
CD44 in clinicopathological features of adult T cell leukemia. Leuk Res. 
2011;35:1484–90.
 27. McAllister SS, Gifford AM, Greiner AL, Kelleher SP, Saelzler MP, Ince TA, 
et al. Systemic endocrine instigation of indolent tumor growth requires 
osteopontin. Cell. 2008;133:994–1005.
 28. Elkabets M, Gifford AM, Scheel C, Nilsson B, Reinhardt F, Bray MA, et al. 
Human tumors instigate granulin‑expressing hematopoietic cells that 
promote malignancy by activating stromal fibroblasts in mice. J Clin 
Invest. 2011;121:784–99.
 29. Ota D, Kanayama M, Matsui Y, Ito K, Maeda N, Kutomi G, et al. Tumor‑α9β1 
integrin‑mediated signaling induces breast cancer growth and lymphatic 
metastasis via the recruitment of cancer‑associated fibroblasts. J Mol 
Med. 2014;92:1271–81.
 30. Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, et al. 
NOD/SCID/γcnull mouse: an excellent recipient mouse model for engraft‑
ment of human cells. Blood. 2002;100:3175–82.
 31. Zimmerman B, Niewiesk S, Lairmore MD. Mouse models of human T 
lymphotropic virus type‑1‑associated adult T‑cell leukemia/lymphoma. 
Vet Pathol. 2010;47:677–89.
 32. Dewan MZ, Terashima K, Taruishi M, Hasegawa H, Ito M, Tanaka Y, et al. 
Rapid tumor formation of human T‑cell leukemia virus type 1‑infected 
cell lines in novel NOD‑SCID/γcnull mice: suppression by an inhibitor 
against NF‑κB. J Virol. 2003;77:5286–94.
 33. Dewan MZ, Takamatsu N, Hidaka T, Hatakeyama K, Nakahata S, Fujisawa J, 
et al. Critical role for TSLC1 expression in the growth and organ infiltration 
of adult T‑cell leukemia cells in vivo. J Virol. 2008;82:11958–63.
 34. Rittling SR, Matsumoto HN, McKee MD, Nanci A, An XR, Novick KE, et al. Mice 
lacking osteopontin show normal development and bone structure but dis‑
play altered osteoclast formation in vitro. J Bone Miner Res. 1998;13:1101–11.
 35. Mori N, Fujii M, Ikeda S, Yamada Y, Tomonaga M, Ballard DW, et al. Con‑
stitutive activation of NF‑κB in primary adult T‑cell leukemia cells. Blood. 
1999;93:2360–8.
 36. Takeda S, Maeda M, Morikawa S, Taniguchi Y, Yasunaga J, Nosaka K, et al. 
Genetic and epigenetic inactivation of tax gene in adult T‑cell leukemia 
cells. Int J Cancer. 2004;109:559–67.
 37. Zhang J, Yamada O, Matsushita Y, Chagan‑Yasutan H, Hattori T. Transacti‑
vation of human osteopontin promoter by human T‑cell leukemia virus 
type 1‑encoded Tax protein. Leuk Res. 2010;34:763–8.
 38. Tuck AB, Elliott BE, Hota C, Tremblay E, Chambers AF. Osteopontin‑
induced, integrin‑dependent migration of human mammary epithelial 
cells involves activation of the hepatocyte growth factor receptor (Met). J 
Cell Biochem. 2000;78:465–75.
 39. Behera R, Kumar V, Lohite K, Karnik S, Kundu GC. Activation of JAK2/
STAT3 signaling by osteopontin promotes tumor growth in human breast 
cancer cells. Carcinogenesis. 2010;31:192–200.
 40. Kale S, Raja R, Thorat D, Soundararajan G, Patil TV, Kundu GC. Osteopon‑
tin signaling upregulates cyclooxygenase‑2 expression in tumor‑asso‑
ciated macrophages leading to enhanced angiogenesis and melanoma 
growth via α9β1 integrin. Oncogene. 2014;33:2295–306.
 41. Yoshida T, Akatsuka T, Imanaka‑Yoshida K. Tenascin‑C and integrins in 
cancer. Cell Adh Migr. 2015;9:96–104.
 42. Lau LF. CCN1/CYR61: the very model of a modern matricellular protein. 
Cell Mol Life Sci. 2011;68:3149–63.
 43. Ruan K, Bao S, Ouyang G. The multifaceted role of periostin in tumorigen‑
esis. Cell Mol Life Sci. 2009;66:2219–30.
 44. Zhang J, Yamada O, Kida S, Matsushita Y, Yamaoka S, Chagan‑Yasutan 
H, et al. Identification of CD44 as a downstream target of noncanonical 
NF‑κB pathway activated by human T‑cell leukemia virus type 1‑encoded 
Tax protein. Virology. 2011;413:244–52.
 45. Baek JM, Jin Q, Ensor J, Boulbes DR, Esteva FJ. Serum CD44 levels and 
overall survival in patients with HER2‑positive breast cancer. Breast Can‑
cer Res Treat. 2011;130:1029–36.
Page 15 of 15Maeda et al. Retrovirology  (2015) 12:99 
 46. Anborgh PH, Mutrie JC, Tuck AB, Chambers AF. Role of the metastasis‑
promoting protein osteopontin in the tumour microenvironment. J Cell 
Mol Med. 2010;14:2037–44.
 47. Mueller MM, Fusenig NE. Friends or foes—bipolar effects of the tumour 
stroma in cancer. Nat Rev Cancer. 2004;4:839–49.
 48. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 
2006;6:392–401.
 49. Räsänen K, Vaheri A. Activation of fibroblasts in cancer stroma. Exp Cell 
Res. 2010;316:2713–22.
 50. Li X, O’Regan AW, Berman JS. IFN‑γ induction of osteopontin expression 
in human monocytoid cells. J Interferon Cytokine Res. 2003;23:259–65.
 51. Yu XQ, Fan JM, Nikolic‑Paterson DJ, Yang N, Mu W, Pichler R, et al. IL‑1 up‑
regulates osteopontin expression in experimental crescentic glomerulo‑
nephritis in the rat. Am J Pathol. 1999;154:833–41.
 52. Shi X, Bai S, Li L, Cao X. Hoxa‑9 represses transforming growth factor‑β‑
induced osteopontin gene transcription. J Biol Chem. 2001;276:850–5.
 53. Kaomongkolgit R, Manokawinchoke J, Sanchavanakit N, Pavasant P, 
Sumrejkanchanakij P. Fibronectin supports TNF‑α‑induced osteopontin 
expression through β1 integrin and ERK in HN‑22 cells. Arch Oral Biol. 
2010;55:101–7.
 54. Ruffell B, Affara NI, Coussens LM. Differential macrophage programming 
in the tumor microenvironment. Trends Immunol. 2012;33:119–26.
 55. Hsu HP, Shan YS, Lai MD, Lin PW. Osteopontin‑positive infiltrating tumor‑
associated macrophages in bulky ampullary cancer predict survival. 
Cancer Biol Ther. 2010;10:144–54.
 56. Imano M, Okuno K, Itoh T, Ishimaru E, Satou T, Shiozaki H. Increased 
osteopontin‑positive macrophage expression in colorectal cancer stroma 
with synchronous liver metastasis. World J Surg. 2010;34:1930–6.
 57. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, et al. Tumor‑associated 
macrophages and survival in classic Hodgkin’s lymphoma. N Engl J Med. 
2010;362:875–85.
 58. Nishime C, Kawai K, Yamamoto T, Katano I, Monnai M, Goda N, et al. 
Innate response to human cancer cells with or without IL‑2 receptor 
common γ‑chain function in NOD background mice lacking adaptive 
immunity. J Immunol. 2015;195:1883–90.
 59. Liguori M, Solinas G, Germano G, Mantovani A, Allavena P. Tumor‑asso‑
ciated macrophages as incessant builders and destroyers of the cancer 
stroma. Cancers. 2011;3:3740–61.
 60. Dai J, Li B, Shi J, Peng L, Zhang D, Qian W, et al. A humanized anti‑oste‑
opontin antibody inhibits breast cancer growth and metastasis in vivo. 
Cancer Immunol Immunother. 2010;59:355–66.
 61. Shojaei F, Scott N, Kang X, Lappin PB, Fitzgerald AA, Karlicek S, et al. 
Osteopontin induces growth of metastatic tumors in a preclinical model 
of non‑small lung cancer. J Exp Clin Cancer Res. 2012;31:26.
 62. Heider KH, Kuthan H, Stehle G, Munzert G. CD44v6: a target for antibody‑
based cancer therapy. Cancer Immunol Immunother. 2004;53:567–79.
 63. Katagiri YU, Sleeman J, Fujii H, Herrlich P, Hotta H, Tanaka K, et al. CD44 
variants but not CD44 s cooperate with β1‑containing integrins to permit 
cells to bind to osteopontin independently of arginine‑glycine‑aspartic 
acid, thereby stimulating cell motility and chemotaxis. Cancer Res. 
1999;59:219–26.
 64. Gurtner K, Hessel F, Eicheler W, Dörfler A, Zips D, Heider KH, et al. Com‑
bined treatment of the immunoconjugate bivatuzumab mertansine and 
fractionated irradiation improves local tumour control in vivo. Radiother 
Oncol. 2012;102:444–9.
 65. Ishida T, Utsunomiya A, Iida S, Inagaki H, Takatsuka Y, Kusumoto S, et al. 
Clinical significance of CCR4 expression in adult T‑cell leukemia/lym‑
phoma: its close association with skin involvement and unfavorable 
outcome. Clin Cancer Res. 2003;9:3625–34.
 66. Ito A, Ishida T, Yano H, Inagaki A, Suzuki S, Sato F, et al. Defucosylated anti‑
CCR4 monoclonal antibody exercises potent ADCC‑mediated antitumor 
effect in the novel tumor‑bearing humanized NOD/Shi‑scid,IL‑2Rγnull 
mouse model. Cancer Immunol Immunother. 2009;58:1195–206.
 67. Ishida T, Ueda R. Antibody therapy for adult T‑cell leukemia‑lymphoma. 
Int J Hematol. 2011;94:443–52.
 68. Mi Z, Bhattacharya SD, Kim VM, Guo H, Talbot LJ, Kuo PC. Osteopontin 
promotes CCL5‑mesenchymal stromal cell‑mediated breast cancer 
metastasis. Carcinogenesis. 2011;32:477–87.
 69. Wu Y, Li YY, Matsushima K, Baba T, Mukaida N. CCL3‑CCR5 axis regu‑
lates intratumoral accumulation of leukocytes and fibroblasts and 
promotes angiogenesis in murine lung metastasis process. J Immunol. 
2008;181:6384–93.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
